New CAR t-cell therapy takes on hard-to-treat leukemia

NCT ID NCT06281847

Not yet recruiting Disease control Sponsor: Advesya SAS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a new treatment called CCTx-001 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. CCTx-001 is a type of immunotherapy that uses a patient's own immune cells, modified to target a protein called IL-1RAP found on leukemia cells. The trial has two phases: the first finds the safest dose, and the second checks how well it works. About 143 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CCTx-001 (a CAR T-cell therapy targeting IL-1RAP)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat acute myeloid leukemia that has come back or not responded to standard therapy.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. CAR T-cell therapies can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA, IN RELAPSE

Contacts and locations

Locations

Besançon Regional and University Hospital

Besançon, France
Hospital Saint Louis

Paris, France
Karolinska University Hospital

Stockholm, Sweden
Ludwig-Maximilians University of Munich

Munich, Germany
University Hospital Ulm

Ulm, Germany
Vall d'Hebron University Hospital

Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.